Clinical trial NCT02187159: Treatment of Pain Associated With Fibromyalgia
Official title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain Associated With Fibromyalgia
Keywords: pain
fibromyalgia
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2014-07-10
Enrollment: 1270
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Able to give written informed consent
* Able to complete subject-reported questionnaires per the investigator's judgment
* At screening, subjects must meet the 1990 American College of Rheumatology (ACR) criteria for FM, i.e. widespread pain present for at least 3 months and pain in at least 11 of 18 specific tender point sites. In addition, the 2010 ACR criteria must be met:
* Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
* Symptoms have been present at a similar level for at least 3 months
* The subject does not have a disorder that would otherwise explain the pain
* ADPS of ≥ 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to randomization (based on completion of at least 4 daily pain diaries during the 7-day baseline period prior to randomization)
* Subject must have documented evidence of a fundoscopic examination (with pupil dilation) within 12 months prior to screening or at screening.
* Women of child-bearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during the study and for 4 weeks after study completion.

Exclusion Criteria:

* Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (e.g. severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months prior to screening that in the opinion of the investigator would interfere with study participation or assessment of safety and tolerability
* Anticipation of initiation or significant change to normal daily exercise routines or need for ongoing use of concomitant medications or non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety
* Unable to undergo pre-study washout of prohibited concomitant medications
* Subjects who are at risk of suicide as defined by their responses to the Columbia-Suicide Severity Rating Scale (C-SSRS) or in the opinion of the investigator. Note: Patients answering "yes" to any of the questions about active suicidal ideation/intent/behaviors occurring within the past 12 months must be excluded (C-SSRS Suicide Ideation section - Questions 3, 4, or 5; C-SSRS Suicidal Behavior section, any of the suicide behaviors questions). Such patients should be referred immediately to a mental health professional for appropriate evaluation.
* Current severe or uncontrolled major depressive disorder or anxiety disorders as assessed by the Mini-international Neuropsychiatric Interview (MINI) mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study.
* Any diagnosis of lifetime bipolar disorder or psychotic disorder
* Subjects with pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that in the opinion of the investigator, would confound assessment or self-evaluation of the pain associated with FM.
* Subjects with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
* Abuse or dependence of prescription medications, street drugs, or alcohol within the last 1 year
* Any history of a malignancy other than basal cell carcinoma within the past 5 years
* A diagnosis of untreated sleep apnea or initiation of treatment for sleep apnea within the past 3 months
* Pregnancy or breast-feeding, or intent to become pregnant during the study period
* Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.
* Known hypersensitivity to alpha2-delta (α2δ) ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
* Subjects who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator to be unlikely to complete the study.
* Abnormal investigative tests (i.e. electrocardiograms \[ECGs\]) and laboratory values judged by the investigator to be clinically significant at screening, with particular focus on: a. Abnormal renal function defined as calculated creatinine clearance (CrCl) \< 60 mL/min determined by the central laboratory using the modified Cockcroft-Gault equation; blood urea nitrogen\> 1.5 × upper limit of normal (ULN); creatine kinase \> 3.0 × ULN; serum creatinine \> 1.6 mg/dL (\> 141.4 μmol/L); b. Abnormal liver function defined as aspartate aminotransferase (AST) \> 2.0 × ULN, alanine aminotransferase (ALT) \> 2.0 × ULN; alkaline phosphatase \> 1.5 × ULN; total bilirubin\> 1.2 × ULN. If a subject has total bilirubin \> 1.2 ULN, unconjugated and conjugated bilirubin fractions should be analyzed and only subjects documented to have Gilbert's syndrome may be enrolled.

Primary outcomes:
measure: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
Secondary outcomes:
measure: Number of Participants Who Answered "Much Improved or Better" on the Patient Global Impression of Change (PGIC) Scale at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 13 postdose
measure: Change From Baseline to Week 13 in Fibromyalgia Index Questionnaire (FIQ) Total Score in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 13 postdose
measure: Change From Baseline to Week 13 in Multidimensional Fatigue Inventory (MFI-20) General Fatigue Score in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Hospital Anxiety and Depression Scale (HADS) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Short Form 36 (SF-36) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in EuroQol Five Dimensions Questionnaire (EQ-5D) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Average Daily Sleep Interference Score (ADSIS) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: The Number of Participants Reporting Optimal Sleep at Week 13 on the Medical Outcomes Study (MOS) Sleep Scale in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 13 postdose
measure: Change From Baseline to Week 13 in the Brief Pain Inventory Short Form (BPI-SF) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Proportion of Days a Rescue Medication Was Used in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 1 to Week 13 postdose
Other outcomes:
Locations:
city: Mobile
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Scottsdale
country: United States
state: Arizona
city: Little Rock
country: United States
state: Arkansas
city: Fresno
country: United States
state: California
city: Glendale
country: United States
state: California
city: Orange
country: United States
state: California
city: Oxnard
country: United States
state: California
city: Richmond
country: United States
state: California
city: Sacramento
country: United States
state: California
city: San Diego
country: United States
state: California
city: Santa Ana
country: United States
state: California
city: Santa Barbara
country: United States
state: California
city: Simi Valley
country: United States
state: California
city: New London
country: United States
state: Connecticut
city: Bradenton
country: United States
state: Florida
city: Brandon
country: United States
state: Florida
city: DeBary
country: United States
state: Florida
city: Fort Myers
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Homestead
country: United States
state: Florida
city: Lake Mary
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: North Miami
country: United States
state: Florida
city: Ocala
country: United States
state: Florida
city: Plant City
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Alpharetta
country: United States
state: Georgia
city: Atlanta
country: United States
state: Georgia
city: Atlanta
country: United States
state: Georgia
city: Columbus
country: United States
state: Georgia
city: Savannah
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Meridian
country: United States
state: Idaho
city: Chicago
country: United States
state: Illinois
city: Gurnee
country: United States
state: Illinois
city: Naperville
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: West Des Moines
country: United States
state: Iowa
city: Shawnee Mission
country: United States
state: Kansas
city: Wichita
country: United States
state: Kansas
city: Lexington
country: United States
state: Kentucky
city: Monroe
country: United States
state: Louisiana
city: Traverse City
country: United States
state: Michigan
city: Jackson
country: United States
state: Mississippi
city: Omaha
country: United States
state: Nebraska
city: Las Vegas
country: United States
state: Nevada
city: Brooklyn
country: United States
state: New York
city: Manhasset
country: United States
state: New York
city: New York
country: United States
state: New York
city: Staten Island
country: United States
state: New York
city: Benson
country: United States
state: North Carolina
city: Greensboro
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Salisbury
country: United States
state: North Carolina
city: Fargo
country: United States
state: North Dakota
city: Cleveland
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Dayton
country: United States
state: Ohio
city: Garfield Heights
country: United States
state: Ohio
city: Middleburg Heights
country: United States
state: Ohio
city: Tiffin
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Tulsa
country: United States
state: Oklahoma
city: Salem
country: United States
state: Oregon
city: Duncansville
country: United States
state: Pennsylvania
city: Warwick
country: United States
state: Rhode Island
city: Anderson
country: United States
state: South Carolina
city: Charleston
country: United States
state: South Carolina
city: Greer
country: United States
state: South Carolina
city: Rock Hill
country: United States
state: South Carolina
city: Bristol
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: New Tazewell
country: United States
state: Tennessee
city: Austin
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Sealy
country: United States
state: Texas
city: Sugar Land
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
city: Norfolk
country: United States
state: Virginia
city: Richmond
country: United States
state: Virginia
city: Kirkland
country: United States
state: Washington
city: Charleston
country: United States
state: West Virginia
city: Camperdown
country: Australia
state: New South Wales
city: Campsie
country: Australia
state: New South Wales
city: Coffs Harbour
country: Australia
state: New South Wales
city: St. Leonards
country: Australia
state: New South Wales
city: Maroochydore
country: Australia
state: Queensland
city: Sherwood
country: Australia
state: Queensland
city: Southport
country: Australia
state: Queensland
city: Woodsville
country: Australia
state: South Australia
city: Hobart
country: Australia
state: Tasmania
city: Clayton
country: Australia
state: Victoria
city: Malvern East
country: Australia
state: Victoria
city: Burgas
country: Bulgaria
city: Pleven
country: Bulgaria
city: Plovdiv
country: Bulgaria
city: Ruse
country: Bulgaria
city: Sevlievo
country: Bulgaria
city: Sofia
country: Bulgaria
city: Targovishte
country: Bulgaria
city: Varna
country: Bulgaria
city: Tallin
country: Estonia
city: Tartu
country: Estonia
city: Balassagyarmat
country: Hungary
city: Budapest
country: Hungary
city: Debrecen
country: Hungary
city: Esztergom
country: Hungary
city: Kistarcsa
country: Hungary
city: Nyiregyhaza
country: Hungary
city: Szeged
country: Hungary
city: Veszprem
country: Hungary
city: Ahmedabad
country: India
state: Gujarat
city: Surat
country: India
state: Gujarat
city: Bangalore
country: India
state: Karnataka
city: Hubli
country: India
state: Karnataka
city: Pune
country: India
state: Maharashtra
city: Jaipur
country: India
state: Rajasthan
city: Lucknow
country: India
state: VP
city: Baldone
country: Latvia
city: Balvi
country: Latvia
city: Jekabpils
country: Latvia
city: Liepaja
country: Latvia
city: Ogre
country: Latvia
city: Riga
country: Latvia
city: Ventspils
country: Latvia
city: Auckland
country: New Zealand
city: Hamilton
country: New Zealand
city: Nelson
country: New Zealand
city: Tauranga
country: New Zealand
city: Wellington
country: New Zealand
city: Bacau
country: Romania
city: Bucharest
country: Romania
city: Cluj Napoca
country: Romania
city: Oradea
country: Romania
city: Targu Mures
country: Romania
city: Ivanovo
country: Russian Federation
city: Krasnoyarsk
country: Russian Federation
city: Moscow
country: Russian Federation
city: Nizhniy Novgorod
country: Russian Federation
city: Orenburgsky
country: Russian Federation
city: Pyatigorski
country: Russian Federation
city: St. Petersburg
country: Russian Federation
city: Stavropol
country: Russian Federation
city: Vladikavkaz
country: Russian Federation
city: Yaroslav
country: Russian Federation
city: Banska Bystrica
country: Slovakia
city: Bratislava
country: Slovakia
city: Dubnica Nad Vahom
country: Slovakia
city: Galanta
country: Slovakia
city: Krompachy
country: Slovakia
city: Piestany
country: Slovakia
city: Presov
country: Slovakia
city: Reading
country: United Kingdom
state: Berkshire
city: Penzance
country: United Kingdom
state: Cornwall
city: Chesterfield
country: United Kingdom
state: Derbyshire
city: Poole
country: United Kingdom
state: Dorset
city: Romford
country: United Kingdom
state: Essex
city: Blackpool
country: United Kingdom
state: Lancashire
city: Thornton-cleveleys
country: United Kingdom
state: Lancashire
city: Wigan
country: United Kingdom
state: Lancashire
city: Salford
country: United Kingdom
state: Manchester
city: Southport
country: United Kingdom
state: Merseyside
city: Wellingborough
country: United Kingdom
state: Northamptonshire
city: Barnsley
country: United Kingdom
state: South Yorkshire
city: Cannock
country: United Kingdom
state: Staffordshire
city: North Shields
country: United Kingdom
state: Tyne and Wear
city: Atherstone
country: United Kingdom
state: Warwickshire
city: Dudley
country: United Kingdom
state: WEST Midlands
city: Belfast
country: United Kingdom
city: Leeds
country: United Kingdom
city: Manchester
country: United Kingdom
city: Torpoint
country: United Kingdom
Study officials:
affiliation: Daiichi Sankyo
name: Global Clinical Leader
role: STUDY_DIRECTOR
References:
citation: Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019 Oct;35(10):1825-1835. doi: 10.1080/03007995.2019.1629757. Epub 2019 Jul 9.